ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Monday, October 27, 2025

10:30AM-12:30PM: Abstract Number: 1363

Evaluation of the Clinical Outcome of Baricitinib in Patients with Rheumatoid Arthritis from Multi-center Collaborative Study in Japan: Sub-analysis for Difficult-to-treat RA.

(1347–1375) Rheumatoid Arthritis – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1115

Evaluation Of The Global Toxicity Burden In Patients Treated With Checkpoint Inhibitors Addressed For a Rheumatologic Toxicity And Its Impact On Oncological Outcomes

(1088–1122) Immunological Complications of Medical Therapy Poster

10:30AM-12:30PM: Abstract Number: 1483

Evidence of Early Cardiovascular Dysfunction in Young Systemic Lupus Erythematosus Patients Compared to Older Healthy Controls

(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1312

Evolution of patients with active rheumatoid arthritis: analysis of disease activity trajectories in a tertiary‑care rheumatology department

(1306–1346) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1410

Examining the Interchangeability of Two Different Patient-Reported Global Assessment Measures in an Observational Axial Spondyloarthritis Cohort

(1405–1433) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 0980

Expansion of Viral-Reactive CD8+ T cell Repertoire Stratified by Pathotype in New-onset ACPA+ Rheumatoid Arthritis

(0978–1006) T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

10:30AM-12:30PM: Abstract Number: 1344

Exploring the Factors Associated with the Discontinuation of Tofacitinib in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study

(1306–1346) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 0939

Exploring the Mechanism of Action and Related Biomarkers of BTK Inhibitor/Degrader in Systemic Lupus Erythematosus

(0934–0954) Systemic Lupus Erythematosus – Animal Models Poster

10:30AM-12:30PM: Abstract Number: 1579

Exploring the Pulmonary Vascular Changes on Computed Tomography in predicting progression and mortality of Systemic Sclerosis-associated Interstitial Lung Disease

(1553–1591) Systemic Sclerosis & Related Disorders – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1032

Exploring the role of the gut microbiome in gout: Prospective analysis of dietary fiber intake and the risk of gout

(1007–1037) Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 1229

Extent versus impact: Sex-specific burden of chronic pain in older adults

(1221–1247) Pain in Rheumatic Disease Including Fibromyalgia Poster

10:30AM-12:30PM: Abstract Number: 1625

Factor VIII as a Potential Biomarker of Disease Activity in Relapsing Polychondritis

(1612–1632) Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

10:30AM-12:30PM: Abstract Number: 1014

Factors Associated with Fibromyalgia Diagnosis amongst People Meeting Criteria: Results from UK Biobank

(1007–1037) Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 1036

Factors Associated With Long-term Remission After Drug Discontinuation In IgG4-related Disease: A 3-Year Rule

(1007–1037) Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 1018

Factors Associated with Mortality in Systemic Lupus Erythematosus under a Universal Healthcare System: Results from the CAPTURED Study, a Population-Based Cohort in Catalonia, Spain

(1007–1037) Epidemiology & Public Health Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].